June 1, 2021
June 1, 2021 – The U.S. FDA has approved an expanded plaque psoriasis indication for Cosentyx®
(secukinumab), manufactured by Novartis. The drug is now indicated to
- Have any questions?
- +1-888-INTL-SOS
- support@globalreachhealth.com
Global Reach Health News
June 1, 2021
June 1, 2021 – The U.S. FDA has approved Lybalvi TM (olanzapine/samidorphan) tablets, manufactured by
Alkermes, for the following indications for adult patients
June 1, 2021
June 1, 2021 – The U.S. FDA has granted accelerated approval to TruseltiqTM (infigratinib), manufactured
by BridgeBio and Helsinn Therapeutics, to treat adults who have previously
May 28, 2021
May 28, 2021 – The U.S. FDA has approved an expanded indication for Zipsor® (diclofenac potassium),
manufactured by Assertio Therapeutics, to provide relief of mild to
May 28, 2021
May 28, 2021 – The U.S. FDA has granted accelerated approval to LumakrasTM (sotorasib), manufactured
by Amgen, to treat KRAS G12C-mutated
May 27, 2021
May 27, 2021 – The U.S. FDA has approved Pylarify® (piflufolastat F 18), manufactured by Progenics
Pharmaceuticals, for positron emission tomography (PET) of prostate-specific
May 27, 2021
May 27, 2021 – The U.S. FDA has approved an expanded indication for Yervoy (ipilimumab), manufactured
by Bristol Myers Squibb, to be used in combination with nivolumab to treat
May 27, 2021
May 27, 2021 – The U.S. FDA has approved a new indication for Zeposia® (ozanimod), manufactured by
Bristol Myers Squibb, to treat adults who have moderately to severely